Axxam is an innovative research and discovery organization providing services for the identification and validation of bioactive molecules across the life sciences industry and supporting pharmaceutical and biotech companies from target validation to hit and lead identification.
Products, services, technology
- Cell-free and cell-based (including iPSC) assay development
- High-Throughput Screening campaigns (optical, image-based, electrophysiology, TaqMan, AS-MS, organellar electrophysiology)
- Compound Collections (more than 450.000 small molecules)
- Hit to Lead (integrated biology and chemistry)
- http://www.axxam.com
- +39 02 21 05 61
- Send an email
- Kerstin Maike Schmitz
Some insights
Axxam's ultimate goal is to lead the way in life sciences and create solutions that redefine what is possible, and inspiring a healthier, more sustainable world.
Axxam's clients expressed many times deep gratitude and compliments for the expert quality and dedication delivered by the Axxam scientific team.
Our team consists of early-stage drug discovery experts driven to tackle complex challenges. We prioritize quality, data security, precision, and collaboration. We are integrating AI-based drug discovery, bioinformatics, and advanced computational biology skills.
The Swiss biotech ecosystem can support Axxam by fostering collaborations with innovative biotech companies, facilitating access to cutting-edge technologies, and creating networking opportunities with key stakeholders focused on drug discovery and development.
At Axxam, we connect with key players in pharma, biotech, and life sciences focused on discovering new drugs and improving global health. We collaborate with innovators seeking advanced solutions in assay development, high-throughput screening, and integrated drug discovery.